1. Kazia is raising $50 million through a private placement. 2. Net proceeds will support clinical development of paxalisib for cancer. 3. The funds extend cash runway into late 2028. 4. Analysts project a 1-year price target of $20 for KZIA. 5. KZIA shares increase by 10.49% to $10.11 recently.